Can-Fite Biopharma Ltd
CANF Healthcare Biotechnology
Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
Follow CANF
Can-Fite Biopharma Ltd (CANF) EV/Sales
As of 16 October 2026, Can-Fite Biopharma Ltd (CANF) trades at a EV/Sales of −8.6×. Over the past ten years it has ranged from −8.6× (October 2026) to 17,289× (March 2021) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −7.3× | — |
| FY2024 | 2.2× | 768.89% |
| FY2023 | 0.2× | (99.94%) |
| FY2022 | 446× | (92.67%) |
| FY2021 | 6,085× | (42.24%) |
| FY2020 | 10,535× | 609,987.56% |
| FY2019 | 1.7× | (99.58%) |
| FY2018 | 410× | 402.99% |
| FY2017 | 81.5× | 15.53% |
| FY2016 | 70.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2023 | 281× | (19.75%) |
| Jun 2023 | 350× | — |
| Mar 2023 | −4.4× | — |
| Dec 2022 | 446× | (22.13%) |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CELZ Creative Medical Technology Holdings, Inc. compare | −352× |
| CDIO Cardio Diagnostics Holdings, Inc. compare | −40.1× |
| CANF Can-Fite Biopharma Ltd | −8.6× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| BGMS Bio Green Med Solution, Inc. compare | 0.7× |
| PULM Pulmatrix, Inc. compare | 0.8× |
| IMNN Imunon, Inc. compare | 8.0× |
| ORGS Orgenesis Inc. compare | 15.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)